TNXP Stock Climbs 7%: Retail Bets On $30M Revenue Upside From Tonmya Deal

• Tonmya is the first U.S. Food and Drug Administration-approved treatment for fibromyalgia in adults in more than 15 years.
• The drug is a non-opioid therapy for daily bedtime use to manage chronic pain.
• Investors are also focusing on TNX-4800, Tonix’s antibody to prevent Lyme disease.

Shares of Tonix Pharmaceuticals Holding Corp. (TNXP) drew strong retail interest on Wednesday, rising about 7% after the company announced a new agreement with a major group purchasing organization to broaden access to its fibromyalgia treatment.

Fibromyalgia is a chronic pain condition affecting mostly women, marked by widespread pain, fatigue, poor sleep, and cognitive and mood issues.

TNXP Bets Big On Tonmya

The deal opens coverage for its Tonmya drug to roughly 35 million commercially insured patients in the U.S. Tonmya, launched in November 2025, is the first U.S. Food and Drug Administration (FDA) approved treatment for fibromyalgia in adults in more than 15 years. It is a non-opioid therapy for daily bedtime use to manage chronic pain over the long term.

The agreement marks steady progress in Tonix’s push to broaden patient access. The company is also advancing discussions with Medicare and Medicaid.

“Fibromyalgia patients have experienced dissatisfaction with available therapies, with 85% of first-line treatments failing due to efficacy and tolerability issues. We are committed to providing patient access to Tonmya by continuing to engage with commercial payers on its value and offering a patient support program to help patients access their prescribed medication,” said Seth Lederman, President and CEO.

Lyme Disease Treatment Also In Focus

Investors are also focusing on TNX-4800, Tonix’s long-acting antibody to prevent Lyme disease. The company plans to begin a Phase 2 randomized, double-blind, placebo-controlled field study. It is expected to test a two-dose regimen, with an initial injection in spring followed by a booster in summer.

The main goal is to evaluate protection against Lyme disease over a six-month period. Tonix expects to have study drug supply ready in early 2027, with further testing, including a human challenge study, planned for 2028.

TNXP: How Did Retail Traders React?

Retail sentiment for TNXP on Stocktwits turned ‘extremely bullish’ from bullish’ a day earlier, while message volumes remained ‘high.’

One user said the latest partnership could add at least $30 million in annual revenue.

However, another user expressed disappointment that the stock couldn’t break $15, given the “huge announcement.”

The stock has declined more than 16% so far this year.

Read also: Novavax Tops Expectations On High-Margin Deals – Retail Says ‘It’s The Only Thing That Matters’

For updates and corrections, email newsroom[at]stocktwits[dot]com.